|
|
|
|
About the conference
Cardiovascular adverse effects continue to dominate the industry agenda. A well designed and executed QTc study has the potential to characterise pro-arrythmic risk of products in development.
This major conference will bring together industry, regulators and academic bodies to discuss the scientific and regulatory challenges in QT analysis and reporting.
Our attendees
Meet Heads, Directors and Vice Presidents of:
Cardiovascular Assessment, Cardiovascular Clinical Research, Clinical Pharmacology
Clinical Trials, Early Safety Pharmacology
Exploratory Development, Global Product Safety
Global QT Strategy Leader, Medical Director
Pharmacology Manager, Phase I Trials, Scientific Advisor, Statistics Manager, Therapeutics Product Manager, Translational Medicine.
|
Network with industry peers
|
|
Take part in our revolutionary speed networking
|
And this year's hot topic
Safety Pharmacology World Europe will address the major clinical and regulatory issues involved in safety pharmacology. The meeting will be the sister event to our successful UK meeting.
|
|
|
|
|
|
Reserve an exhibition stand at the Safety Pharmacology World Europe exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
James Hopkins
+44 207 608 7038 |
|
|
|
|
|
|
|
|
|
|
